Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Mounjaro's appetite-suppressing effects within the first one to two weeks of their starting dose, though meaningful weight change typically shows up after four to eight weeks of treatment. Tirzepatide begins working from the first injection, but the body needs time to respond — and the dose you start on is deliberately modest. These are prescription-only medicines; a clinician reviews your suitability before any treatment begins. What you feel, and when, depends on your dose, your physiology, and how consistently the medicine is taken. This page sets out what the evidence actually says, week by week, so you know what to expect.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, tirzepatide starts acting from the first dose, but the early signals are subtle and easy to miss if you're watching the scales instead of your appetite. Most people report feeling full more quickly at meals within the first few days. Some notice they simply don't think about food between meals the way they used to. These are real pharmacological effects, not placebo; if you want to understand how soon Mounjaro takes effect, our dedicated guide explains why fullness arrives sooner and lingers longer from the very first injection.
What you're less likely to feel early on is weight loss itself. The starting dose of 2.5 mg is titrated gradually for tolerability, not peak effect. Think of it as settling your system in before the real work starts. Some people do see a small drop on the scales in the first fortnight (often partly fluid and partly early appetite suppression) but it's not a reliable signal of how the medicine will perform for you longer term.
A quick habit worth building: weigh yourself at the same time each morning, ideally before eating, and note it weekly rather than daily. Day-to-day fluctuation is noise; the four-week trend is the signal. One minute, same condition, once a week.
For most people, the most noticeable side effects land in the first one to two weeks of each new dose. Nausea is the most commonly reported; diarrhoea, constipation, indigestion and tiredness also feature. The lived experience of being on Mounjaro varies considerably from person to person, but the pattern is fairly consistent: discomfort peaks, then eases within days to a couple of weeks as the body adapts.
This cycle can repeat each time the dose increases, though many people find subsequent increases easier than the first. Eating smaller portions, avoiding high-fat or spicy food in the early weeks, and staying well hydrated all help. These aren't coping strategies to push through, they're the standard clinical guidance that accompanies treatment.
Seek urgent medical attention for severe stomach pain that radiates to your back, with or without vomiting; this can be a sign of acute pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as an infrequent but serious risk with GLP-1 medicines. Your Patient Information Leaflet lists the full set of symptoms that warrant same-day contact with a clinician.
Four to eight weeks is the range most often described in clinical experience and consistent with the trial data. In SURMOUNT-1, weight loss was measurable from week four onwards and continued across the 72-week study period, with the largest proportional changes seen as doses increased. At the 15 mg maintenance dose, average body-weight reduction reached around 20–21%, but those participants were months into treatment, not weeks. The SURMOUNT-1 results, published in the New England Journal of Medicine, involved thousands of adults and remain the most cited evidence base for tirzepatide's weight-management effects.
Practically, most people on 2.5 mg see modest early loss. The clinical trajectory accelerates through the titration process as the prescriber increases the dose, typically in four-week steps. That gradual build is intentional, it's where the bulk of the long-term result comes from.
If you're curious how tirzepatide compares to other licensed options, the weight-loss treatment overview covers the landscape plainly. And if you've read enough and want to talk through your own situation, the free consultation connects you with a GPhC-registered prescriber the same day.
A lack of obvious appetite change at 2.5 mg isn't unusual, the starting dose is low by design. The more useful question is whether side effects are manageable and whether you're taking the injection consistently on the same day each week. If four weeks pass without any effect on appetite and without side effects, that's worth raising with your prescriber at the point of dose review. If you want to understand when you start feeling the effects of Mounjaro, our dedicated guide walks through the timeline in detail, because the prescriber's job is ultimately to assess whether a dose increase is appropriate.
What isn't recommended is adjusting timing on your own. The question of whether you can shift your injection day is one our prescribers hear regularly, there are specific rules, and they matter for both safety and effectiveness. The NHS patient guidance on tirzepatide covers what to do if you miss or delay a dose, and your prescriber or aftercare team can advise based on your individual schedule. At nume, aftercare is available seven days a week, not just during business hours.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.